- Home
- AMGN vs APP Comparison
AMGN vs APP Comparison
Compare AMGN & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- APP
- Stock Information
- Founded
- AMGN 1980
- APP 2012
- Country
- AMGN United States
- APP United States
- Employees
- AMGN N/A
- APP N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- APP EDP Services
- Sector
- AMGN Health Care
- APP Technology
- Exchange
- AMGN Nasdaq
- APP Nasdaq
- Market Cap
- AMGN 155.9B
- APP 129.8B
- IPO Year
- AMGN N/A
- APP 2021
- Fundamental
- Price
- AMGN $295.27
- APP $335.10
- Analyst Decision
- AMGN Hold
- APP Buy
- Analyst Count
- AMGN 20
- APP 21
- Target Price
- AMGN $322.30
- APP $411.60
- AVG Volume (30 Days)
- AMGN 2.7M
- APP 5.6M
- Earning Date
- AMGN 08-05-2025
- APP 08-06-2025
- Dividend Yield
- AMGN 3.22%
- APP N/A
- EPS Growth
- AMGN 56.16
- APP 232.19
- EPS
- AMGN 10.94
- APP 5.53
- Revenue
- AMGN $34,126,000,000.00
- APP $5,135,154,000.00
- Revenue This Year
- AMGN $7.73
- APP $21.46
- Revenue Next Year
- AMGN $1.68
- APP $21.38
- P/E Ratio
- AMGN $27.00
- APP $60.61
- Revenue Growth
- AMGN 15.56
- APP 41.63
- 52 Week Low
- AMGN $253.30
- APP $60.67
- 52 Week High
- AMGN $346.85
- APP $525.15
- Technical
- Relative Strength Index (RSI)
- AMGN 55.95
- APP 43.84
- Support Level
- AMGN $291.25
- APP $325.58
- Resistance Level
- AMGN $302.38
- APP $362.64
- Average True Range (ATR)
- AMGN 8.76
- APP 17.76
- MACD
- AMGN 1.17
- APP -0.80
- Stochastic Oscillator
- AMGN 79.42
- APP 35.41
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.